OrthoPediatrics Corp. (Nasdaq: KIDS) announced preliminary unaudited financial highlights for Q3 2025, helping over 37,100 children and generating approximately $61.2 million in net revenue, with a 14% growth domestically and 6% growth internationally. The Company revised its 2025 revenue guidance to $233.5 million to $234.5 million, with an adjusted EBITDA range of $15.0 million to $17.0 million.

During Q3 2025, OrthoPediatrics faced headwinds due to delayed 7D capital sales and challenges in Latin and South America, resulting in a revenue shortfall. The Company reaffirmed its commitment to revenue growth and profitability, aiming for cash flow break-even in 2026. OrthoPediatrics remains a leader in pediatric orthopedics, helping more kids every year.

The estimated net revenue figures for 2025 are preliminary and subject to adjustment post audit. The Company will hold a conference call on October 9, 2025, to discuss the preliminary results and plans to release full Q3 2025 financial results on October 28, 2025. OrthoPediatrics uses non-GAAP financial measures like Adjusted EBITDA to analyze its core business performance, aiming to provide investors with useful supplemental information.

Founded in 2006, OrthoPediatrics focuses on pediatric orthopedics, offering over 80 products in trauma, deformity, scoliosis, and sports medicine. Its global sales network serves the US and over 70 countries. For more information, visit www.orthopediatrics.com. For details on the OrthoPediatrics Specialty Bracing portfolio, visit www.opsb.com. For investor inquiries, contact Philip Taylor at [email protected] or 415-937-5406.

Read more at GlobeNewswire: OrthoPediatrics Corp. Announces Preliminary Third Quarter